Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Gains from Investment Securities (2020 - 2025)

Roivant Sciences (ROIV) has disclosed Gains from Investment Securities for 6 consecutive years, with $19.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities changed N/A year-over-year to $19.6 million, compared with a TTM value of $2.5 million through Dec 2025, down 94.3%, and an annual FY2025 reading of $139.4 million, down 5.21% over the prior year.
  • Gains from Investment Securities was $19.6 million for Q4 2025 at Roivant Sciences, up from -$6.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $154.3 million in Q1 2023 and bottomed at -$11.1 million in Q2 2025.
  • Average Gains from Investment Securities over 5 years is $37.5 million, with a median of $1.2 million recorded in 2021.
  • The sharpest move saw Gains from Investment Securities soared 308.91% in 2024, then tumbled 3468.39% in 2025.
  • Year by year, Gains from Investment Securities stood at $1.2 million in 2021, then skyrocketed by 6822.04% to $80.4 million in 2022, then plummeted by 60.37% to $31.8 million in 2023, then plummeted by 62.22% to $12.0 million in 2024, then skyrocketed by 62.75% to $19.6 million in 2025.
  • Business Quant data shows Gains from Investment Securities for ROIV at $19.6 million in Q4 2025, -$6.0 million in Q3 2025, and -$11.1 million in Q2 2025.